In this context, non-traditional biomarkers (such as NGAL, IL-6, IL-18, KIM-1, L-FABP, TIMP-2, IGFBP7, syndecan-1, and nephrin) have a relevant role to play in the early detection of AKI in preterm newborns with sepsis and in the prevention of CKD and death, in addition to mitigating impacts on the healthcare system. This evidence concerns the gene LCN2 and chronic kidney disease.